CompletedPhase 3NCT01404312
Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)
Studying Primary genito-urinary tuberculosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Richard E. Chaisson, MD, M.DJohns Hopkins University
- Intervention
- Rifapentine (RPT)(drug)
- Enrollment
- 3000 enrolled
- Eligibility
- 13 years · All sexes
- Timeline
- 2012 – 2017
Study locations (30)
- University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States
- University of Southern California CRS, Los Angeles, California, United States
- UCSD Antiviral Research Center CRS, San Diego, California, United States
- Ucsf Hiv/Aids Crs, San Francisco, California, United States
- Harbor-UCLA CRS, Torrance, California, United States
- University of Colorado Hospital CRS, Aurora, Colorado, United States
- Denver Public Health CRS, Denver, Colorado, United States
- The University of Miami AIDS Clinical Research Unit (ACRU) CRS, Miami, Florida, United States
- Northwestern University CRS, Chicago, Illinois, United States
- Boston Medical Center CRS, Boston, Massachusetts, United States
- Henry Ford Hosp. CRS, Detroit, Michigan, United States
- Cooper Univ. Hosp. CRS, Camden, New Jersey, United States
- New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States
- Nyu Ny Nichd Crs, New York, New York, United States
- Columbia P&S CRS, New York, New York, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01404312 on ClinicalTrials.govOther trials for Primary genito-urinary tuberculosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05917210Peer-led Implementation of TB-HIV Education and Adherence Counseling in UgandaYale University
- RECRUITINGNCT07312266Questioning the Epidemiology of Asymptomatic TBBarcelona Institute for Global Health
- RECRUITINGNANCT05842161South Africa Smoking Cessation and Engagement in HIV/TB Care CareMassachusetts General Hospital
- RECRUITINGPHASE3NCT05575518A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary TuberculosisStellah Mpagama
- ACTIVE NOT RECRUITINGPHASE4NCT05118490Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis PatientsThe Aurum Institute NPC
- RECRUITINGNANCT05342064Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered ServiceBaylor College of Medicine